Joint Publication with Kite Pharma and NCI in Blood Journal: Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL

Research recently published in the journal Blood — conducted in a collaborative effort with Kite Pharma, a Gilead company — demonstrates a significant association between the functionality of an anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis’ Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma (NHL). “The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization.

Share This Article
Be in the Know.
The IsoPlexis Data Network
Join 10,000+ top scientists and receive industry pioneers' backed data straight to your inbox.
Your data is in safe hands: we’ll never sell it to third parties and you may always unsubscribe. Privacy Policy.